USD 66.21
(-7.07%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 83.24 Million USD | 19.06% |
2022 | 69.92 Million USD | 4.35% |
2021 | 67 Million USD | 35.12% |
2020 | 49.59 Million USD | 75.16% |
2019 | 28.31 Million USD | 302.63% |
2018 | 7.03 Million USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
2010 | - USD | 0.0% |
2009 | - USD | 0.0% |
2008 | - USD | 0.0% |
2007 | - USD | -100.0% |
2006 | 576 Thousand USD | 0.0% |
2005 | - USD | 0.0% |
2004 | - USD | 0.0% |
2003 | - USD | 0.0% |
2002 | - USD | 0.0% |
2001 | - USD | 0.0% |
2000 | - USD | 0.0% |
1999 | - USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | 90.06 Million USD | 8.57% |
2024 Q1 | 82.95 Million USD | -0.35% |
2024 Q3 | 98.47 Million USD | 9.33% |
2023 FY | 83.24 Million USD | 19.06% |
2023 Q3 | 77.92 Million USD | 0.74% |
2023 Q2 | 77.34 Million USD | 8.46% |
2023 Q1 | 71.31 Million USD | 2.0% |
2023 Q4 | 83.24 Million USD | 6.83% |
2022 Q2 | 67.01 Million USD | 4.48% |
2022 Q4 | 69.92 Million USD | 5.5% |
2022 Q1 | 64.14 Million USD | -4.27% |
2022 FY | 69.92 Million USD | 4.35% |
2022 Q3 | 66.27 Million USD | -1.11% |
2021 Q1 | 52.06 Million USD | 4.98% |
2021 Q3 | 67.45 Million USD | 11.7% |
2021 Q4 | 67 Million USD | -0.66% |
2021 Q2 | 60.38 Million USD | 15.99% |
2021 FY | 67 Million USD | 35.12% |
2020 Q4 | 49.59 Million USD | 14.05% |
2020 FY | 49.59 Million USD | 75.16% |
2020 Q1 | 30.64 Million USD | 8.24% |
2020 Q2 | 35.47 Million USD | 15.75% |
2020 Q3 | 43.48 Million USD | 22.58% |
2019 FY | 28.31 Million USD | 302.63% |
2019 Q1 | 12.68 Million USD | 80.35% |
2019 Q2 | 20.16 Million USD | 58.97% |
2019 Q4 | 28.31 Million USD | 21.45% |
2019 Q3 | 23.31 Million USD | 15.64% |
2018 Q2 | - USD | 0.0% |
2018 FY | 7.03 Million USD | 0.0% |
2018 Q4 | 7.03 Million USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2011 Q4 | - USD | 0.0% |
2011 Q3 | - USD | 0.0% |
2011 Q2 | - USD | 0.0% |
2011 FY | - USD | 0.0% |
2011 Q1 | - USD | 0.0% |
2010 Q1 | - USD | 0.0% |
2010 FY | - USD | 0.0% |
2010 Q4 | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2009 Q3 | -121.74 Million USD | -235.8% |
2009 Q2 | -36.25 Million USD | 71.56% |
2009 Q1 | -127.47 Million USD | 0.0% |
2009 FY | - USD | 0.0% |
2009 Q4 | - USD | 100.0% |
2008 FY | - USD | 0.0% |
2008 Q1 | - USD | 0.0% |
2008 Q4 | - USD | 0.0% |
2008 Q3 | - USD | 0.0% |
2008 Q2 | - USD | 0.0% |
2007 Q4 | - USD | -100.0% |
2007 FY | - USD | -100.0% |
2007 Q1 | 493 Thousand USD | -14.41% |
2007 Q2 | - USD | -100.0% |
2007 Q3 | 492 Thousand USD | 0.0% |
2006 Q3 | 1.82 Million USD | 1.34% |
2006 Q4 | 576 Thousand USD | -68.37% |
2006 Q2 | 1.79 Million USD | 0.0% |
2006 Q1 | - USD | 0.0% |
2006 FY | 576 Thousand USD | 0.0% |
2005 Q2 | - USD | 0.0% |
2005 Q3 | - USD | 0.0% |
2005 FY | - USD | 0.0% |
2005 Q4 | - USD | 0.0% |
2005 Q1 | - USD | 0.0% |
2004 Q3 | - USD | 0.0% |
2004 Q1 | - USD | 0.0% |
2004 FY | - USD | 0.0% |
2004 Q4 | - USD | 0.0% |
2004 Q2 | - USD | 0.0% |
2003 Q2 | - USD | 0.0% |
2003 Q4 | - USD | 0.0% |
2003 Q3 | - USD | 0.0% |
2003 Q1 | - USD | 0.0% |
2003 FY | - USD | 0.0% |
2002 Q1 | - USD | 0.0% |
2002 Q2 | - USD | 0.0% |
2002 Q3 | - USD | 0.0% |
2002 FY | - USD | 0.0% |
2002 Q4 | - USD | 0.0% |
2001 Q4 | - USD | 0.0% |
2001 FY | - USD | 0.0% |
2001 Q1 | - USD | 0.0% |
2001 Q3 | - USD | 0.0% |
2001 Q2 | - USD | 0.0% |
2000 Q4 | - USD | 0.0% |
2000 Q3 | - USD | 0.0% |
2000 Q2 | - USD | 0.0% |
2000 FY | - USD | 0.0% |
2000 Q1 | - USD | 0.0% |
1999 FY | - USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
uniQure N.V. | 12.02 Million USD | -592.349% |
Agios Pharmaceuticals, Inc. | 19.07 Million USD | -336.402% |
Amicus Therapeutics, Inc. | 59.69 Million USD | -39.453% |
Atara Biotherapeutics, Inc. | 9.7 Million USD | -757.696% |
bluebird bio, Inc. | 22.91 Million USD | -263.227% |
Cara Therapeutics, Inc. | 2.82 Million USD | -2851.01% |
Imunon, Inc. | - USD | -Infinity% |
Editas Medicine, Inc. | - USD | -Infinity% |
IQVIA Holdings Inc. | - USD | -Infinity% |
Mettler-Toledo International Inc. | 385.86 Million USD | 78.426% |
Myriad Genetics, Inc. | 20.1 Million USD | -314.169% |
Neurocrine Biosciences, Inc. | 38.3 Million USD | -117.358% |
Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -7.544% |
Verastem, Inc. | - USD | -Infinity% |
Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 98.999% |
Waters Corporation | 516.23 Million USD | 83.874% |
Thermo Fisher Scientific Inc. | 5.08 Billion USD | 98.364% |
Biogen Inc. | 2.52 Billion USD | 96.706% |
Nektar Therapeutics | 16.1 Million USD | -417.036% |
Perrigo Company plc | 1.14 Billion USD | 92.703% |
Dynavax Technologies Corporation | 53.29 Million USD | -56.217% |
Illumina, Inc. | 587 Million USD | 85.818% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Iovance Biotherapeutics, Inc. | 10.37 Million USD | -702.622% |
Heron Therapeutics, Inc. | 42.11 Million USD | -97.692% |
Unity Biotechnology, Inc. | - USD | -Infinity% |
BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 92.481% |
Sangamo Therapeutics, Inc. | - USD | -Infinity% |
Evolus, Inc. | 10.99 Million USD | -656.938% |
Adicet Bio, Inc. | - USD | -Infinity% |
Aclaris Therapeutics, Inc. | - USD | -Infinity% |
Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 96.774% |
Esperion Therapeutics, Inc. | 65.62 Million USD | -26.858% |
FibroGen, Inc. | 41.56 Million USD | -100.284% |
Agilent Technologies, Inc. | 1.03 Billion USD | 91.926% |
OPKO Health, Inc. | 65.69 Million USD | -26.715% |
Homology Medicines, Inc. | - USD | -Infinity% |
Geron Corporation | - USD | -Infinity% |
Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 6.616% |
Exelixis, Inc. | 17.32 Million USD | -380.563% |
Viking Therapeutics, Inc. | - USD | -Infinity% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | - USD | -Infinity% |
Zoetis Inc. | 2.56 Billion USD | 96.753% |
Axsome Therapeutics, Inc. | 15.13 Million USD | -450.036% |
Abeona Therapeutics Inc. | -2.44 Million USD | 3506.219% |
Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 88.732% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -192.869% |
Sarepta Therapeutics, Inc. | 322.85 Million USD | 74.215% |
Corcept Therapeutics Incorporated | 7.73 Million USD | -976.947% |
Halozyme Therapeutics, Inc. | 127.6 Million USD | 34.759% |
Blueprint Medicines Corporation | 21.22 Million USD | -292.254% |
TG Therapeutics, Inc. | 39.82 Million USD | -109.045% |
Incyte Corporation | 62.97 Million USD | -32.198% |
Emergent BioSolutions Inc. | 328.9 Million USD | 74.689% |